Letters to the Editor

Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971; 30: 213–7

Andersson O. Rontgenbilden vid spondylarthritis ankylopoetica. Nord Med 1937; 30: 2000–2

Cawley MID , Chalmers TM , Kellgren JH . Destructive lesions of the vertebral bodies in ankylosing spondylitis. Ann. Rheum Dis 1972; 41: 345–58

Pastershank SP , Resnick D. Pseudarthrosis in ankylosing spondylitis. J Can Assoc Radiol 1980; 31: 234–5

Rivelis M , Freiberger RH . Vertebral destruction at unfused segments in late ankylosing spondylitis. Radiology 1969; 93: 251–6

Dunn NA , Preston BJ , Jones JK Lloyd . Unexplained backache in longstanding ankylosing spondylitis. Br Med J 1985; 291: 1632–4

Chlebowski R , Tong M , Weissman J. Hepatocellular carcinoma: Diagnostic and prognostic features in North American patients. Cancer 1984; 53: 2701–6

Lee Y , Stagnet M , Simmon R. Two stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat Rep 1975; 63: 1721–6

Sachs E , DiBisceglie AM , Dusheiko GM . Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: A pilot study. Br J Cancer 1985; 52: 105–9

Nair PV , Tong MJ , Kempf R , Co R , Lee S-D , Venturi CL . Clinical, serologic and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma. Cancer 1985; 56: 1018

Singer DRJ , Jenkins AP , Gupta S , Evans DJ . Minimal change nephropathy in the acquired immune deficiency syndrome. Br Med J 1985; 291: 868

Treser G , Cherubin C , Lonergan ET . Renal lesions in narcotic addicts. Am J Med 1974; 57: 687–94

Sapira JD , Ball JC , Penn H. Causes of death among institutionalized narcotic addicts. J. Chronic Dis 1970; 22: 733

Koffler A , Friedler RM , Massry SG . Acute renal failure due to nontraumatic rhabdomyolysis. Ann Intern Med 1976; 85: 23–8

Faure N. Failure of long term luteinizing hormone releasing hormone to suppress testosterone. Br Med J 1984; 289: 1380–1

Lock MTWT , De Jong FH , Chadha DR , Schroder FH . Long-term effects of buserelin on plasma testosterone and luteinizing hormone concentrations. Lancet 1985; ii: 1236–7

Brinkley D. Quality of life in cancer trials. Br Med J 1985; 291: 685–6

Guthrie D , Maskens AP . Clinical trials in ovarian cancer. In: Hudson CN , ed. Ovarian cancer. Oxford: Oxford University Press, 1985: 334–49

Faure N , Lemay A , Laroch G . Preliminary results on the clinical efficacy and safety of androgen inhibition by LHRH against, alone or combined with antiandrogen in the treatment of prostatic carcinoma. Prostate 1983; 4: 601–24